Elsevier Joins ORCID in Announcing Launch of ORCID Registry
Automatic import from Scopus helps researchers set up their ORCID profiles more easily
Amsterdam, October 16, 2012 – Elsevier, a world-leading provider of scientific, technical, and medical information products and services, is pleased to join with ORCID to today announce the official launch of the ORCID Registry. Elsevier, a founding sponsor and launch partner of ORCID, expects to integrate ORCID with many of its products and services.
ORCID, the Open Researcher and Contributor ID, seeks to remedy the systemic name ambiguity problems seen in scholarly research by assigning unique identifiers linkable to an individual's research output. ORCID will facilitate an open and transparent linking mechanism between ORCID, other ID schemes, and research objects such as publications, grants and patents.
At launch, researchers and scholars will be able to register for an ORCID identifier, create ORCID records, and manage privacy settings. They will also be able to link to and synchronize their ORCID identifier record data with external systems including Scopus, the world’s largest abstract and citation database of peer-reviewed literature. Researchers will be able to link to their Scopus Author Profiles from their ORCID records, saving them time when setting up their ORCID profile and allowing Scopus to automatically keep their ORCID bibliography up to date. Next year, Scopus will incorporate ORCID data into the Scopus author profiling process to increase the accuracy of the Scopus profiles and automatically propagate work that researchers do to clean up their ORCID profiles.
“We hope to integrate ORCID with many of our products and services over time, increasing interoperability with other services and saving time for our authors, reviewers, editors and customers,” says Chris Shillum, Vice President of Product Management, Platform and Content at Elsevier and ORCID board member. “The launch of ORCID is the culmination of years of hard work and we are proud to be a founding member of this community-wide initiative.”
In addition to the Scopus tool, ORCID data will be added to the SciVal suite of products, to further enhance the accuracy of researcher profiles, and enable increased interoperability with customers’ own data. Elsevier’s Publishing group also plans to integrate ORCIDs into the manuscript submission process; this will save authors time when going through the submission process, and enable automatic updating of author bibliographies when articles are published.
# # #
ORCID is an open, non-profit, community-based effort to provide a persistent registry of unique researcher identifiers and a transparent method of linking research activities to these identifiers. Starting in October, individuals may register for an ORCID identifier at http://orcid.org. For more about ORCID, see http://about.orcid.org or contact the Executive Director email@example.com.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, Reaxys, MD Consult and Mosby’s Nursing Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai’s Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Covering the world's research literature, Scopus is the largest abstract and citation database of peer-reviewed literature. Featuring smart tools to track, analyze and visualize research, Scopus was designed and developed with input from over 500 users and librarians internationally. Its unique database contains abstracts and references from nearly 19,500 peer-reviewed journals from more than 5,000 publishers worldwide, ensuring broad interdisciplinary coverage. In addition, Scopus not only offers users citation information about the articles covered, but also directly integrates Web and patent searches. Direct links to subscribed full-text articles, library resources and other applications like reference management software, make Scopus quicker, easier and more comprehensive to use than any other literature research tool.
About Elsevier’s SciVal Suite
Designed to support the many stages of the research planning cycle, Elsevier’s SciVal® suite of solutions and services provides critical information about research performance, funding and expertise to enable informed decision-making and drive successful outcomes. SciVal delivers the objective and analytical insight needed to maximize the performance of individuals, teams and organizations.
SciVal tools leverage Scopus® data, Elsevier’s trusted source of bibliometric data, to offer innovative and authoritative solutions. Current offerings include: SciVal Spotlight, a strategic tool that generates unique institutional and country maps of existing and emerging research strengths based on an interdisciplinary perspective of current performance; SciVal Funding, a searchable database of funding opportunities and awarded grants; SciVal Strata, a research performance tool that offers users the flexibility to construct relevant contextual data to evaluate research teams or individual researchers, using a range of indicators based on Scopus data; and SciVal Experts, a semantic technology-based application that enables researchers and administrators to identify expertise and enable collaboration within the institution and across organizations.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).Media contact
Senior Manager Corporate Relations Elsevier
+31 20 485 27 36